|Bid||70.50 x 1200|
|Ask||70.65 x 900|
|Day's Range||70.00 - 71.62|
|52 Week Range||69.56 - 181.83|
|Beta (5Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 04, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||132.32|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 887 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
A potentially misinterpreted clinical trial readout from January may mean a market opportunity for bargain hunters.
Sarepta Therapeutics (NASDAQ: SRPT) continues to make progress selling its drugs to treat Duchenne muscular dystrophy (DMD). In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights discuss Sarepta's fourth-quarter results and why investors should still be focused on the company's pipeline. Brian Orelli: Moving on to Sarepta Therapeutics, which is focused on Duchenne's muscular dystrophy.